期刊文献+

真核表达质粒pcDNA3.1(+)-h/mCD44v6的构建和鉴定

Construction and determination of a recombinant eukaryotic plasmid pcDNA3.1(+)-h/mCD44v6
下载PDF
导出
摘要 目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,测序后插入pcD-NA3.1(+)真核表达质粒,构建重组真核表达质粒pcD-NA3.1(+)-h/mCD44v6,经限制内切酶酶切分析及测序鉴定后,用脂质体转染B16细胞,通过RT-PCR扩增出B16/pcDNA3.1(+)-h/mCD44v6细胞株中h/mCD44v6全段基因cDNA。结果经4轮PCR,成功扩增出h/mCD44v6的cD-NA全长基因,成功构建了真核表达质粒pcDNA3.1(+)-h/mCD44v6,通过RT-PCR方法证实该质粒能在B16真核细胞中正确表达;建立了稳定的细胞株B16/pcDNA3.1(+)-h/mCD44v6。结论成功克隆和构建了h/mCD44v6的真核表达质粒pcDNA3.1(+)-h/mCD44v6,为进一步研究h/mCD44v6的新功能和免疫治疗奠定了基础。 Aim To construct a eukaryotic plasmid containing the chimeric human and mouse CD44 splice variant 6 gene (h/ mCD44v6) and test the expression of the plasmid in the eukaryotic cell. Methods The full-length cDNA of h/mCD44v6 encoding gene was obtained by PCR. Then the cDNA was inserted into the eukaryotic expression vector pcDNA3.1 ( + ) ,the resultant recombinant plasmid was confirmed by restriction endonuelease and sequencing, then designated as pcDNA3.1 ( + )-h/ mCD44v6. The recombinant eukaryotic plasmid pcDNA3.1 ( + )-h/mCD44v6 was transfected into eukaryotic cell B16 by LIPOFECTIN. RT-PCR was used to certify whether the purpose gene was correctly expressed in B16/pcDNA3.1 ( + )-h/ mCD44v6 cell. Results About 358 bp cDNA of h/mCD44v6 was obtained by four steps of overlapping PCR. The recombinant eukaryotic expression plasmid pcDNA3. 1 ( + )-h/mCD44v6 was successfully constructed and expressed in the B16 cells. Conclusion This recombinant pcDNA3. 1 ( + )-h/mCD44v6 plasmid will provide a basis for further study on the unknown function of h/mCD4 v6.
出处 《中国药理学通报》 CAS CSCD 北大核心 2009年第8期1111-1113,共3页 Chinese Pharmacological Bulletin
基金 国家高技术研究发展计划(863计划)资助项目(No2001AA217131) 海南省教育厅资助项目(NoHjkj2006-26) 海南省自然科学基金重点项目(No061002) 海南省自然科学基金项目(No806129)
关键词 粘附分子CD44拼接变异体6 质粒 真核表达 细胞株 基因 克隆 CD44 splice variant 6 plasmid eukaryotic expression cell line gene clone
  • 相关文献

参考文献8

  • 1Heider K H,Kuthan H,Stehle G,et al. CD44v6:a target for antibody-based cancer therapy [ J ]. Cancer Immunol lmmunother, 2004,53(7) :567 -79.
  • 2Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells [J]. Cell, 1991,65 ( 1 ) : 13 - 24.
  • 3Rudy W, Hofmann M, Schwartz-Albiez R, et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants : each one individually suffices to confer metastatic behavior [ J ]. Cancer Res, 1993 ,53 (6) : 1262 - 8.
  • 4Gm-iec N, Marcellin L, Gairard B, et al. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma [ J ]. Cli Exp Metastasis, 1996,14 ( 5 ) :434 - 9.
  • 5Verel I, Heider K H, Siegmund M, el al. Tumor targeting properties of monoelonal antibodies with different affinity for target antigen CD44v6 in nude mice bearing head-and-neck cancer xenografts [ J]. lnt J Cancer,2002,99(3 ) :396 -402.
  • 6Pontus K E, Borjesson, Ernst J, etal Phase I therapy study with ( 186 ) Re-labeled humanized monoclonal antibody BIWA 4( bivatuzumab) in patients with head and neck squamons cell carcinoma [ J ]. Clin Cancer Res,2003,9:3961 - 72.
  • 7Riechelmann H, Sauter A, Golze W, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma [ J ]. Oral Oncol, 2008,44 ( 9 ) : 823 - 9.
  • 8魏于全,田聆.异种同源基因、分子进化与肿瘤治疗[J].自然科学进展,2002,12(2):140-144. 被引量:6

二级参考文献3

  • 1谭芳 张玉静.遗传与进化.分子遗传学[M].北京:科学出版社,2000.450-463.
  • 2魏于全.抗肿瘤自身免疫反应与异种细胞疫苗研究进展.细胞生物学与肿瘤免疫学研究进展[M].北京:军事医学科学出版社,2000.208.
  • 3魏于全.肿瘤疫苗研究进展——利用异种细胞及异种基因进行肿瘤免疫治疗及基因治疗[J].中国肿瘤生物治疗杂志,1999,6:176-176.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部